The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation.

Autor: Ridha-Salman H; College of Pharmacy, Al-Mustaqbal University, Babylon, Hillah, 51001, Iraq. hayder80.ridha@gmail.com., Al-Zubaidy AA; Department of Pharmacology, College of Medicine, University of Warith Al-Anbiyaa, Karbala, Iraq., Abbas AH; College of Pharmacy, Al-Mustaqbal University, Babylon, Hillah, 51001, Iraq., Hassan DM; Pedodontic, Orthodontic and Preventive Department, College of Dentistry, Babylon University, Babylon, Iraq., Malik SA; College of Pharmacy, Al-Mustaqbal University, Babylon, Hillah, 51001, Iraq.
Jazyk: angličtina
Zdroj: Naunyn-Schmiedeberg's archives of pharmacology [Naunyn Schmiedebergs Arch Pharmacol] 2024 Sep 10. Date of Electronic Publication: 2024 Sep 10.
DOI: 10.1007/s00210-024-03406-y
Abstrakt: Psoriasis is a life-long immune-mediated dermatosis with thickened, reddish, and flaky skin patches. Canagliflozin is a gliflozin antidiabetic with non-classical remarkable antioxidative, anti-inflammatory, anti-proliferative, and immune-modulating effects. The aim of this study is to examine the probable effects of topical canagliflozin on a mouse model of imiquimod-provoked psoriasis-like dermatitis. The study evaluated 20 Swiss white mice, sorted haphazardly into 4 groups of 5 animals each. Every mouse, with the exception of the control group, had imiquimod applied topically to their shaved backs for 7 days. The control group included healthy mice that were not given any treatment. Mice in the other three groups underwent topical treatment with vehicle (induction group), 0.05% clobetasol propionate ointment (clobetasol group), or 4% canagliflozin emulgel (canagliflozin 4% group) on exactly the same day as imiquimod cream was administered. Topical canagliflozin markedly lowered the intensity of imiquimod-provoked psoriasis eruptions, featuring redness, glossy-white scales, and acanthosis, while also correcting histopathological aberrations. Canagliflozin administration to imiquimod-exposed animals resulted in significantly decreased cutaneous concentrations of inflammatory mediators such as IL-8, IL-17, IL-23, and TNF-α, with raised levels of IL-10. Canagliflozin further lowered proliferative factors involving Ki-67 and PCNA, diminished oxidative indicators such as MDA and MPO, and augmented the activity of antioxidant markers, notably SOD and CAT. Canagliflozin might alleviate the imiquimod-induced animal model of psoriasis, probably thanks to its profound anti-inflammatory, antioxidant, antiangiogenic, and antiproliferative activities.
(© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: